Peregrine Pharmaceuticals Inc., of Tustin, Calif., reported that an investigator-sponsored trial of its monocolonal antibody bavituximab for patients with Stage II or Stage III rectal adenocarcinoma has been initiated. The open-label Phase I trial will enroll up to 18 patients to receive the antibody in combination with capcitabine and radiation for eight weeks.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST